Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06123286 · ClinicalTrials.gov registry record · Early Phase 1
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
A Early Phase 1 study of Breast Cancer and Joint Pain, sponsored by Philip Chang.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06123286 is a Early Phase 1 study of Breast Cancer and Joint Pain that is actively recruiting participants, run by Philip Chang. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06123286, a Early Phase 1 study of Breast Cancer and Joint Pain, is actively recruiting participants, sponsored by Philip Chang.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. There is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to Tart Cherry or fish oil in isolation in an obese breast cancer population experiencing AIMSS. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.
Conditions Studied
Interventions
- DRUG Tart Cherry
- DRUG Omega 3 FA (Fish Oil)
Study Locations (2)
California
- Cedars-Sinai Medical Center - Los Angeles
- CS Cancer at the Hunt Cancer Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2027-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06123286
The ClinicalTrials.gov registry entry for NCT06123286 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Philip Chang, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tart Cherry is the first listed.
NCT06123286 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06123286 about?
NCT06123286 is a clinical study titled "Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms". Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more rece...
What is the current status of trial NCT06123286?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-12. Estimated completion is 2027-10.
What conditions does trial NCT06123286 study?
This clinical trial studies the following conditions: Breast Cancer, Joint Pain, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).
What interventions are being tested in trial NCT06123286?
The interventions under investigation include: Tart Cherry (DRUG), Omega 3 FA (Fish Oil) (DRUG).
Who is sponsoring clinical trial NCT06123286?
This trial is sponsored by Philip Chang, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06123286 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.